Quantcast

Latest Combination drugs Stories

2014-07-10 23:02:13

In-demand research report “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” prepared by GlobalData is now available at MarketPublishers.com. According to the study, the six major pharma markets are expected to post an around 4% CAGR through 2018. London, UK (PRWEB) July 10, 2014 Notwithstanding its considerable patient pool across the US and 5EU acne market has remained stagnant over the past few decades, with no new drugs coming into the arena. The...

Little baby get an injection
2014-07-02 05:34:48

redOrbit Staff & Wire Reports - Your Universe Online Parents worried about having their children vaccinated take note: a new study published Tuesday in the journal Pediatrics has found that immunization-related side-effects are extremely rare, and that there is no evidence linking them to serious health issues such as leukemia or autism spectrum disorders (ASD). According to Liz Szabo of USA Today, researchers from Boston Children’s Hospital, the VA Greater Los Angeles Healthcare...

2014-06-26 12:26:45

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlookhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable...

2014-06-26 08:28:58

Report Examines Unintentional Acetaminophen Overdose and Success of Consumer Education Efforts WASHINGTON, June 26, 2014 /PRNewswire-USNewswire/ -- The Acetaminophen Awareness Coalition (AAC), a coalition of leading health, healthcare provider, and consumer organizations, today released "Acetaminophen: How It's Used, Preventing Overdose and What We Can Do to Promote Safe Use," a report and educational resource to drive safe and appropriate use of America's most common drug ingredient. The...

2014-06-18 12:37:20

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharma_leader_series_top_25_ophthalmic_drug_manufacturers_2014_2024.html Report DetailsNew study shows you commercial prospects for leading eye drug producersWhat does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report...

2014-06-11 08:28:16

- Agreement needs to be reached on the post-marketing obligation for continued evaluation of CV outcomes - SAN DIEGO, June 11, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the Company's investigational medication being evaluated for weight loss. The new Prescription Drug User Fee Act (PDUFA) action date has...

2014-06-03 12:37:54

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Asthma and COPD Therapies: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/diseases/asthma/asthma_copd_therapies.html Report DetailsNew study reveals sales potential of this large, expanding marketSee what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial...

2014-06-02 08:29:51

- FDA will Adjust the PDUFA Date by One Day Based on Revised Calendar Calculation - SAN DIEGO, June 2, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) has informed the Company that the FDA intends to reassign the Prescription Drug User Fee Act (PDUFA) action date for the NB32 New Drug Application to June 11, 2014, one day beyond the original assignment. The FDA noted that due to an...

2014-05-08 16:26:47

SAN DIEGO, May 8, 2014 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the first quarter ended March 31, 2014. "With the June 10 PDUFA date for NB32 quickly approaching, we are excited to be working closely with our partner for North America, Takeda Pharmaceuticals, on final preparations to launch NB32, if approved, with a field force of approximately 900 sales...

2014-05-01 08:36:45

SAN DIEGO, May 1, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the first quarter 2014, on Thursday, May 8, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). Orexigen management will host the call and webcast to discuss financial results and recent business...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related